Both reactions depend on ATP, and the reaction mechanisms are similar
this could improve tolerability and, therefore, have a positive impact on quality of life as side effects such as fatigue, headaches, or dizziness associated with treatment become less frequent
Generally, GSH binding shows relatively strong affinity to the G-site (near the active cysteine residue) and weak affinity to the H-site in the case of WT proteins
Dihydroergotamine has also been shown to be an inhibitor of cytochrome P450 3A catalyzed reactions and rare reports of ergotism have been obtained from patients treated with dihydroergotamine and macrolide antibiotics (e.g., troleandomycin, clarithromycin, erythromycin), and in patients treated with dihydroergotamine and protease inhibitors (e.g., ritonavir), presumably due to inhibition of cytochrome P450 3A metabolism of ergotamine (see CONTRAINDICATIONS)